6 results about "Intravenous route" patented technology

The invention provides a CD40 targeted medicine for realizing tumor immunodiagnosis and treatment by regulating PTPN1 / PTPN2 as well as a preparation method and application of the CD40 targeted medicine. The drug comprises a drug-loading membrane layer, perfluorinated compound PFC and glycerin are wrapped in the drug-loading membrane layer, the drug-loading membrane layer is coupled with a CD40 agonist, and the drug-loading membrane layer comprises phospholipid, cholesterol, a functionalized lipid polymer and AC484. The drug shows excellent biological stability and can be delivered to tumor tissue through a respiratory tract or a vein route; according to the medicine, accumulation and distribution of the medicine in the body are dynamically monitored through a 1H / 19F magnetic resonance imaging technology, noninvasive evaluation of the tumor state is achieved, immunotherapy is accurately guided, and therefore the tumor treatment effect is remarkably improved.

A medical device system is provided for guiding implantation of a medical electrical lead. The system includes processing circuitry configured to receive first patient body image data and second patient body image data and register the first patient body image data and the second patient body image data. The processing circuitry may be further configured to receive a signal from at least one location sensor disposed at a known distance from a feature of a removable outer sheath of a delivery tool configured to deliver an extravascular lead to an implant site of a patient via a non-transvenous pathway. The processing circuitry may determine from the location sensor signal a location of a feature of the removable outer sheath in a coordinate system space corresponding to the second patient body image data.

There is provided a transvenous approach for accessing and targeting neural treatment sites to relieve a variety of clinical indications, including peripheral neuropathy. A neurosome approach is described that includes one or more target nerves to receive selective cryoneurolysis via a target vein. A range of different freeze and thaw cycles are performed via the target vein to induce a desired thermal treatment temperature range for selective sensory loss without adverse impact or minimal impact to associated motor nerves. The target nerves and veins are selected to combine the treatment of the identified neurosome for pain relief in addition to the regenerative properties of cryoneurolysis.

Antibody drugs have been proposed to treat allergic diseases, but the route of administration is limited to intravenous route, which is inconvenient for patients. In addition, novel agents that inhibit kinases such as NIK are always needed to develop effective drugs and other products to treat allergic diseases. At least one compound selected from mangiferin 8a (formula (1)), norathyriol (formula (2)), mangiferin (formula (3)), 1,3,5,6-tetrahydroxyxanthone (formula (4)), xanthohydrol (formula (5)), α-mangostin (formula (6)), and γ-mangostin (formula (7)) having a xanthone structure can improve allergic diseases and can be effective when taken orally.

The present invention provides a neurosteroid derivative having the structure shown in formula (I) and uses thereof. The neurosteroid derivative having the structure shown in formula (I) provided by the present invention has significantly higher bioavailability than the prior art and can be administered via a non-intravenous route for the treatment and / or prevention of GABA-A receptor-mediated diseases. [C14] TIFF2026501665000029.tif46149

Present invention relates to aqueous compositions comprising cyclooxygenase-2 (COX-2) inhibitors, preferably Etoricoxib or Celecoxib or Valdecoxib or Paracoxib or salts thereof at least two solubilizers at 4.2% w / v to 19% w / v, preferably between 4.2% w / v to 18% w / v having viscosity in range of 1.0 cps to 3 cps, wherein the Etoricoxib and Celecoxib or salts thereof are present in amount ranging from 0.14 mg to 4 mg. The composition is suitable for the parenteral route of administration primarily for ready to dilute and ready to infuse which alternatively can be administered as intramuscular, intraarterial, intraocular, intraventricular, intravenous routes; also for subcutaneous, cutaneous delivery. The invention further provides a method for preparing the said composition.